50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Merck to buy Imago for $1.35 billion to broaden portfolio of blood disorder drugs

Published 11/21/2022, 06:53 AM
Updated 11/21/2022, 11:50 AM
© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo
XLRN
-

By Raghav Mahobe

(Reuters) -Merck & Co Inc said on Monday it will acquire cancer drug developer Imago BioSciences Inc for a total equity value of $1.35 billion to expand its portfolio of blood disorder treatments.

The offer of $36 per share in cash for Imago represents a nearly 107% premium to the company's last close. Imago's shares more than doubled in early trading to $35.53.

With Merck's blockbuster cancer immunotherapy Keytruda expected to lose key patents in 2028, the company has been trying to expand its drug portfolio.

Last year, it bought Acceleron Pharma (NASDAQ:XLRN) for about $11.5 billion to gain access to its experimental therapy for treating a type of high blood pressure.

Merck was reported to be in talks to buy cancer-focused biotech Seagen Inc over the summer, for nearly $40 billion, but a deal did not materialize.

Estimated revenue potential of the Imago deal is probably not enough to fill the loss of exclusivity gap left by Keytruda later in this decade, BMO Capital Markets analyst Evan Seigerman said.

Seigerman added that he expects the company to do more deals that can help fill the revenue gap from Keytruda's patent loss.

Imago, which develops drugs for the treatment of bone marrow-related diseases, is currently testing its lead drug bomedemstat in mid-stage studies for treating certain types of rare blood cancers.

Merck did not provide details on the effect of the Imago deal on its financial results in the near term.

© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo

The company said it will initiate a tender offer to acquire all outstanding Imago shares through a unit, which will be merged into Imago upon completion of the offer.

The companies expect to close the transaction in the first quarter of 2023.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.